The PennZone

  • Home
  • Business
  • Health
  • Education
  • Financial
  • Non-profit
  • Entertainment
  • Legal
  • Women

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
The PennZone/10287268

Trending...
  • $3.9M Q1 2025 Revenue Following $39M in Cybersecurity Contracts for Education and Transportation Sectors: Cycurion, Inc
  • Malvern Coffee Company Launches with Signature Blend, King's Cup: A Bold, Locally Roasted Expression of Community and Craft
  • $77.8 Million in Revenue Through April 2025, Confirms Full-Year Guidance; Fast-Track to 400 Million Run Rate; $1 Billion Target After Key Acquisition
~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has recently announced that their Phase 1 study evaluating DVX201, an allogeneic natural killer (NK) cell therapy, for the treatment of patients hospitalized with COVID-19 has been accepted for publication in Molecular Therapy Methods and Clinical Development.

The study, conducted by Coeptis Therapeutics, a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, demonstrated the safety and feasibility of DVX201 as a potential treatment for patients with active SARS-CoV-2 infections. The results have been accepted for publication in Molecular Therapy Methods and Clinical Development.

According to the accepted manuscript, this is the first known study to demonstrate the safety of adoptive immunotherapy with allogeneic, off-the-shelf NK cells in patients with active COVID-19. This is particularly significant for high-risk patients who are at risk for disease progression.

DVX201 is an innovative NK cell therapy derived from pooled donor cord blood CD34+ cells. It is the first allogeneic NK cell adoptive immunotherapy used clinically that offers a scalable, consistent, and cost-effective solution to barriers in the allogeneic cell therapy space.

The study also reported no adverse events related to DVX201 infusions. This includes no cytokine release syndrome (CRS), which can be a serious complication of immunotherapy treatments. Additionally, observations from the study showed rapid improvements in oxygenation and pulmonary radiographic findings in patients who received DVX201 infusions. Some patients were even able to be discharged from the hospital within days of receiving the treatment.

More on The PennZone
  • Garipoli Appointed Sertoma International Treasurer
  • Mauro Schnaidman named as Managing Director in Miami, Florida
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
  • Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague

Dr. Joshua Hill, associate professor and physician at Fred Hutch Cancer Center and corresponding author of the study stated that despite advances in treatment and prevention strategies for SARS-CoV-2, COVID-19 still results in substantial morbidity in certain patient populations. This highlights the ongoing need for additional therapeutic options, especially among immune compromised individuals. While the study was not designed to assess efficacy, the findings demonstrate the safety and potential utility of NK cell therapy as a complementary therapeutic strategy for viral infections in high-risk patients.

Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed excitement about the positive results and looks forward to sharing the full findings in Molecular Therapy Methods and Clinical Development. He also mentioned that these results, along with their recently announced expanded license agreement with Deverra, further strengthens Coeptis' role in the fight against infectious diseases.

To access the full publication in Molecular Therapy Methods and Clinical Development, please visit: https://www.cell.com/molecular-therapy-family/m...

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their product portfolio includes assets licensed from Deverra Therapeutics such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology. They are also developing a universal multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.

More on The PennZone
  • Robert Michael & Co. Launches New Real Estate Website to Serve Central Florida Homebuyers and Sellers
  • CRAACO Conference Focuses on Getting More Clinical Trials Into Healthcare Systems
  • IFFA 2025 Shines Bright as Mukesh Modi Welcomes Rio Rocket and Award Winner Lulu Lopez
  • Kemeny, Ramp & Renaud Expands Legal Team with Attorney Baruch Kraut
  • WOA Entertainment Group Unveils Independent No.1's: Breakthrough Artists II —A Celebration of Indie Excellence

Coeptis' business model is centered around maximizing the value of their current product portfolio through various agreements such as in-license agreements, out-license agreements, co-development relationships, and strategic partnerships to expand their product rights and offerings. They are particularly focused on targeting cancer and infectious diseases. The company is headquartered in Wexford, PA. For more information on Coeptis, please visit https://coeptistx.com/.

This article serves as a cautionary note regarding the potential of Coeptis' products and rights. Any forward-looking statements made in this article are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the success of clinical trials, regulatory approvals, and market acceptance of their products. Readers are advised to refer to the company's filings with the Securities and Exchange Commission for a more comprehensive understanding of these risks and uncertainties.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Cyta Cyprus Selects Axiros' AXESS Platform for Cloud-Native, Data-Driven Device Management
  • DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions
  • 123Invent Inventor Develops Improved Storage Solution for Hair Accessories
  • Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
  • VNBTC Becomes The Top Crypto Investment Platform As Its Bitcoin Cloud Mining Solution Goes Viral
  • Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
  • Urgent Reform Demanded to Stop Child Abuse in Youth Behavioral Facilities
  • WELLNESS PIONEERS BET BIG ON THE RACQUET SPORTS BOOM WITH BALLERS, A HOSPITALITY-DRIVEN SOCIAL SPORTS CONCEPT WITH AMBITIOUS GROWTH TRAJECTORY
  • Cyrus O'Leary's Mini Cream Pies - The Latest Dessert Innovation from Sara Lee Frozen Bakery Delivers Indulgence in Single-Servings
  • Emerge Apps Launches Mod Performance Suite: A New Era of Work Comp Selling for Insurance Agents
  • Imagine waking up every day knowing you can earn $, and actually making it happen. Are you ready to change your life? Let's get started!
  • ETH Price Prophecy: Is $3,000 Within Reach? — HASHJ Best Cloud Mining Platform Focuses on Gas-Optimized Mining
  • Mental Health Watchdog Calls Baker Acting of Children in Florida a Parental Rights Violation
  • Injured While Using Rideshare?
  • Wealthywet's Miami Swim Week 2025 Debut Signals a New Era of Luxury in Swimwear
  • Luxury Waterfront Home in Porto Sol Community Now Available Through Innovative "Name Your Price" Approach
  • GOODBY SILVERSTEIN & PARTNERS TAKES HOME "BEST OF SHOW" AT THE 2025 AAF AMERICAN ADVERTISING AWARDS
  • BREAKING CONSUMER ALERT: Carvana's "Certified" Luxury SUV Buyer Exposes Legal & Mechanical Trauma 'Presses' Charges of Duress, Deception, and Delay
  • Imagen Golf Announces New Partnership with The Hurricane Golf Tour
  • Malvern Coffee Company Launches with Signature Blend, King's Cup: A Bold, Locally Roasted Expression of Community and Craft

Popular on PennZone

  • WWSG Announces Exclusive Speaking Partnership with Patrick McGee, Author of 'Apple in China' - 165
  • Call for Papers Deadline Approaching – Don't Miss Your Shot to Speak at the OpenSSL Conference 2025! - 132
  • Koplon Implant & Family Dentistry Receives National Recognition as One of the Best Dental Implant Practices in the U.S - 126
  • Premium Domain Name "Feedri.com" Now Available for Acquisition After $8,500 Offer - 126
  • Cycurion Wins $33M Cybersecurity Contract for State Colleges, Also $6M from Transportation Agency: Cycurion, Inc. (Stock Symbol: CYCU) is Undervalued - 122
  • $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST) - 121
  • The Great Reset, the First Photorealistic AI Film Makes History at the Cannes Film Festival - 109
  • Fairmint Releases Whitepaper for Open Captable Protocol (OCP) to Advance On-Chain Equity Securities
  • Bluumly Chosen as Finalist for the 2025 MIT Sloan CIO Symposium's Innovation Showcase
  • DivX Launches Ultimate Guide to Free MP4 Playback

Similar on PennZone

  • United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
  • 123Invent Inventor Develops New Product for Use with Scratch-Off Tickets (PPA-236)
  • Mauro Schnaidman named as Managing Director in Miami, Florida
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • Robert Michael & Co. Launches New Real Estate Website to Serve Central Florida Homebuyers and Sellers
  • CRAACO Conference Focuses on Getting More Clinical Trials Into Healthcare Systems
  • Remember Internet Pioneers NetCom Solutions & Network Solutions? Founder Emmit J. McHenry is Now Leading the Emerging Cybersecurity Firm Cycurion
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
  • Benchmark Federal Credit Union to Merge into Franklin Mint Federal Credit Union
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us